nemoci-sympt/HEPATOLOGIE/firboza-jater/terapie-zmirneni
Maresin-1 (MaR1)
- Derivative of omega-3 docosahexaenoic acid (DHA)
- Pro-resolutive and anti-inflammatory effects
Animal model of chronic hepatic damage
- Sprague-Dawley rats were induced with liver fibrosis by injections of diethylnitrosamine (DEN)
- Treated with or without MaR1 for four weeks
MaR1-treated animals
- AST and ALT were normalized in comparison with DEN alone
- Hepatic architecture was improved
- Inflammation and necrotic areas were reduced
- Cell proliferation, assessed by the mitotic activity index and the expression of Ki-67, was increased in the MaR1-treated group.
- MaR1 attenuated liver fibrosis and oxidative stress induced by DEN
- TNF-alpha and IL-1beta were reduced in MaR1-treated animals
- IL-10, an anti-inflammatory cytokine, increased
- MaR1 inhibited the translocation of the p65 subunit of NF-kappaB
- Increasing the activation of Nrf2
- MaR1 treatment reduced the levels of the pro-fibrotic mediator TGF-beta and its receptor
- Normalizing the hepatic levels of IGF-1, a proliferative agent
- MaR1 as a potential therapeutic agent in fibrosis and other liver pathologies.
